Cargando…
Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia
OBJECTIVE: To describe effectiveness of repeat dexamethasone for bronchopulmonary dysplasia (BPD) and to evaluate adverse effects on growth. STUDY DESIGN: Retrospective study of infants treated with 1 or 2 courses of dexamethasone for BPD. Effectiveness was defined as successful step-down in respira...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184867/ https://www.ncbi.nlm.nih.gov/pubmed/34103670 http://dx.doi.org/10.1038/s41372-021-01125-3 |
_version_ | 1783704666544013312 |
---|---|
author | Cuna, Alain Quiqley, Anastasia Varghese, Kevin Ciccolari-Micaldi, Greta Oliveros, Christian Cheng, An-Lin Norberg, Michael Truog, William E. |
author_facet | Cuna, Alain Quiqley, Anastasia Varghese, Kevin Ciccolari-Micaldi, Greta Oliveros, Christian Cheng, An-Lin Norberg, Michael Truog, William E. |
author_sort | Cuna, Alain |
collection | PubMed |
description | OBJECTIVE: To describe effectiveness of repeat dexamethasone for bronchopulmonary dysplasia (BPD) and to evaluate adverse effects on growth. STUDY DESIGN: Retrospective study of infants treated with 1 or 2 courses of dexamethasone for BPD. Effectiveness was defined as successful step-down in respiratory support by end of treatment. Adverse effects on growth were analyzed and compared to untreated controls. RESULTS: A total of 132 dexamethasone-treated infants were identified. In total, 52% (69/132) of infants treated with initial dexamethasone achieved step-down in respiratory support compared to 38% (20/52) of infants with repeat dexamethasone. Growth trajectory did not significantly differ among infants treated with 1 or 2 courses of dexamethasone compared with controls (weight: P = 0.23, length: P = 0.68, and head circumference: P = 0.77). CONCLUSIONS: Repeat dexamethasone for BPD was less effective in weaning respiratory support compared to initial course. Changes in growth parameters to discharge were comparable between controls and infants treated with 1 or 2 dexamethasone courses. |
format | Online Article Text |
id | pubmed-8184867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-81848672021-06-08 Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia Cuna, Alain Quiqley, Anastasia Varghese, Kevin Ciccolari-Micaldi, Greta Oliveros, Christian Cheng, An-Lin Norberg, Michael Truog, William E. J Perinatol Article OBJECTIVE: To describe effectiveness of repeat dexamethasone for bronchopulmonary dysplasia (BPD) and to evaluate adverse effects on growth. STUDY DESIGN: Retrospective study of infants treated with 1 or 2 courses of dexamethasone for BPD. Effectiveness was defined as successful step-down in respiratory support by end of treatment. Adverse effects on growth were analyzed and compared to untreated controls. RESULTS: A total of 132 dexamethasone-treated infants were identified. In total, 52% (69/132) of infants treated with initial dexamethasone achieved step-down in respiratory support compared to 38% (20/52) of infants with repeat dexamethasone. Growth trajectory did not significantly differ among infants treated with 1 or 2 courses of dexamethasone compared with controls (weight: P = 0.23, length: P = 0.68, and head circumference: P = 0.77). CONCLUSIONS: Repeat dexamethasone for BPD was less effective in weaning respiratory support compared to initial course. Changes in growth parameters to discharge were comparable between controls and infants treated with 1 or 2 dexamethasone courses. Nature Publishing Group US 2021-06-08 2021 /pmc/articles/PMC8184867/ /pubmed/34103670 http://dx.doi.org/10.1038/s41372-021-01125-3 Text en © The Author(s), under exclusive licence to Springer Nature America, Inc. 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Cuna, Alain Quiqley, Anastasia Varghese, Kevin Ciccolari-Micaldi, Greta Oliveros, Christian Cheng, An-Lin Norberg, Michael Truog, William E. Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
title | Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
title_full | Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
title_fullStr | Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
title_full_unstemmed | Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
title_short | Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
title_sort | effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184867/ https://www.ncbi.nlm.nih.gov/pubmed/34103670 http://dx.doi.org/10.1038/s41372-021-01125-3 |
work_keys_str_mv | AT cunaalain effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT quiqleyanastasia effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT varghesekevin effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT ciccolarimicaldigreta effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT oliveroschristian effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT chenganlin effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT norbergmichael effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia AT truogwilliame effectivenessandsafetyofrepeatdexamethasoneforbronchopulmonarydysplasia |